伊格列净 T2385

Product Introduction
Bioactivity


英文名: Ipragliflozin

描述: Ipragliflozin (ASP1941) 是一种口服有效的，选择性的 SGLT2抑制剂，对人 SGLT2 和 SGLT1，大鼠 SGLT2 和 SGLT1，小鼠 SGLT2 和 SGLT1 的 IC50分别为 7.38 和 1876 nM，6.73 和 1166 nM，5.64 和 1380 nM。Ipragliflozin 具有抗糖尿病活性。

激酶实验: Inhibition of TNF-α synthesis: TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 70 mg/mL (173.07 mM)


关键字: SGLT | Inhibitor | ASP 1941 | Sodium-dependent glucose cotransporters | inhibit | Ipragliflozin | ASP-1941

相关产品: SGL5213 | Phloretin | T-1095 | O-Desethyl Dapagliflozin | Mizagliflozin | LY2794193 | Ertugliflozin L-pyroglutamic acid | Empagliflozin | Enavogliflozin | SGLT inhibitor-1

相关库: Drug Repurposing Compound Library | Glycometabolism Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | GPCR Compound Library | Anti-Cancer Approved Drug Library | Highly Selective Inhibitor Library

伊格列净 T2385信息由TargetMol中国为您提供，如您想了解更多关于伊格列净 T2385报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途